Top

Journal of Diabetes & Metabolic Disorders

Published in:

01-12-2020 | Insulins | Research article

Gender dependent differences in lipid metabolism in individuals with type 2 diabetes mellitus

Authors: Abhijit A. Ghadge, Abhay M. Harsulkar, Arundhati G. Diwan, Aniket A. Kuvalekar

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2020

Abstract

Aim

The present study investigates gender dependent effects of insulin resistance on lipid profile and adipocytokines in individuals with diabetes receiving oral antidiabetic drugs (OADs). The aim was also to reveal the changes in the expression of genes involved in lipid metabolism and inflammation.

Methods

Lipid profile, adipocytokine levels and homeostatic model assessment of insulin resistance (HOMA-IR) was assessed in 100 patients with diabetes (M = 43, F = 57) matched for age and gender with healthy individuals (M = 45, F = 55). The expression pattern of genes was analyzed by quantitative real time PCR.

Results

Males consuming metformin with other drugs exhibited a positive association between HOMA-IR and cholesterol, triglyceride and very low density lipoprotein (VLDL). Females consuming only metformin and metformin with other drugs, showed a positive association of HOMA-IR with cholesterol and a negative association with adiponectin. In males and females with diabetes, a comparable expression of peroxisome proliferator activated receptor γ (PPARγ) while higher expression of sterol regulatory element binding protein 1 (SREBP1) was observed. Expression of fatty acid synthase (FAS), long chain acyl CoA Synthetases (ACSL), malonyl-CoA-acyl carrier protein transacylase (MCAT) and nuclear factor kappa β (NFkβ) was higher in men with diabetes than healthy males. Expression of tumor necrosis factor α (TNF-α) was higher in males and females with diabetes than respective healthy genders.

Conclusion

Insulin resistance adversely affects lipid profile, adipocytokines in males with type 2 diabetes. Expression of genes involved in lipid metabolism and inflammation is found to be undesirably and differentially altered in both the genders.

Steiner GA. A new perspective in the treatment of dyslipidemia: can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus? Treat Endocrinol. 2005;4:311–7. https://doi.org/10.2165/00024677-200504050-00004.CrossRefPubMed

Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150–9. https://doi.org/10.1038/ncpendmet1066.CrossRefPubMed

Shashikala E, Motgi S, Rao RBNV, et al. Study of lipid lowering effects of oral antidiabetic drugs in type 2 diabetes mellitus patients. Int J Basic Clin Pharmacol. 2018;7(1):126–32. https://doi.org/10.18203/2319-2003.ijbcp20175687.CrossRef

Kashi Z, Mahrooz A, Kianmehr A, Alizadeh A. The role of metformin response in lipid metabolism in patients with recent-onset type 2 diabetes: hba1c level as a criterion for designating patients as responders or nonresponders to metformin. PLoS One. 2016;11(3):e0151543. https://doi.org/10.1371/journal.pone.0151543.CrossRefPubMedPubMedCentral

Halimi S, Schweizer A, Minic B, Foley J, Dejager S. Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag. 2008;4:481–92. https://doi.org/10.2147/VHRM.S2503.CrossRefPubMedPubMedCentral

Zabielski P, Chacinska M, Charkiewicz K, Baranowski M, Gorski J, Blachnio-Zabielska AU. Effect of metformin on bioactive lipid metabolism in insulin-resistant muscle. J Endocrinol. 2017;233(3):329–40. https://doi.org/10.1530/JOE-16-0381.CrossRefPubMed

Zhou X, Xu J, Shi Y, Ye JM. Discovery of novel anti-diabetic drugs by targeting lipid metabolism. Curr Drug Targets. 2015;16(12):1372–80. https://doi.org/10.2174/1389450116666150223120829.CrossRefPubMed

Bragt MC, Plat J, Mensink M, et al. Anti-inflammatory effect of rosiglitazone is not reflected in expression of NFkappaβ-related genes in peripheral blood mononuclear cells of patients with type 2 diabetes mellitus. BMC Endocr Disord. 2009;9:8. https://doi.org/10.1186/1472-6823-9-8.CrossRefPubMedPubMedCentral

Stumvoll M, Goldstein BJ, Van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333–46. https://doi.org/10.1016/S0140-6736(05)61032-X.CrossRefPubMed

10.

Ghadge A, Harsulkar A, Karandikar M, Pandit V, Kuvalekar A. Comparative anti-inflammatory and lipid-normalizing effects of metformin and omega-3 fatty acids through modulation of transcription factors in diabetic rats. Genes Nutr. 2016;11:10. https://doi.org/10.1186/s12263-016-0518-4.CrossRefPubMedPubMedCentral

11.

Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the kelly west award lecture 2008. Diabetes Care. 2010;33:442–9. https://doi.org/10.2337/dc09-0749.CrossRefPubMedPubMedCentral

12.

Lee JM, Kim SR, Yoo SJ, Hong OK, Son HS, Chang SA. The relationship between adipokines, metabolic parameters and insulin resistance in patients with metabolic syndrome and type 2 diabetes. J Int Med Res. 2009b;37(6):1803–12. https://doi.org/10.1177/147323000903700616.CrossRefPubMed

13.

Diwan AG, Kuvalekar AA, Dharamsi S, Vora AM, Nikam VA, Ghadge AA. Correlation of serum adiponectin and leptin levels in obesity and type 2 diabetes mellitus. Indian J Endocr Metab. 2018;22:93–9. https://doi.org/10.4103/ijem.IJEM_491_15.CrossRef

14.

Kim JY, Ahn SV, Yoon JH, Koh SB, Yoon J, Yoo BS, et al. Prospective study of serum adiponectin and incident metabolic syndrome the arirang study. Diabetes Care. 2013;36:1547–53. https://doi.org/10.2337/dc12-0223.CrossRefPubMedPubMedCentral

15.

Ghadge AA, Khaire AA. Leptin as a predictive marker for metabolic syndrome. Cytokine. 2019;121:154735. https://doi.org/10.1016/j.cyto.2019.154735.CrossRefPubMed

16.

Kim H, Haluzik M, Gavrilova O, Yakar S, Portas J, Sun H, et al. Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. Diabetologia. 2004;47(12):2215–25. https://doi.org/10.1007/s00125-004-1581-6.CrossRefPubMed

17.

Rasouli N, Raue U, Miles LM, Lu T, di Gregorio GB, Elbein SC, et al. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab. 2005;288:930–4. https://doi.org/10.1152/ajpendo.00522.2004.CrossRef

18.

Blanco-Colio LM, Martín-Ventura JL, Gomez-Guerrero C, et al. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. Eur J Pharmacol. 2008;586:259–65. https://doi.org/10.1016/j.ejphar.2008.02.042.CrossRefPubMed

19.

Legato MJ, Gelzer A, Goland R, Ebner SA, Rajan S, Villagra V, et al. Gender-specific care of the patient with diabetes: review and recommendations. Gend Med. 2006;3(2):131–58. https://doi.org/10.1016/s1550-8579(06)80202-0.CrossRefPubMed

20.

Flockhart DA, Desta Z. Pharmacogenetics of drug metabolism. In Clinical and Translational Science. Elsevier Inc. 2009;301–317. https://doi.org/10.1016/B978-0-12-373639-0.00021-2

21.

Huang SM, Miller M, Toigo T, et al. Evaluation of drugs in women: regulatory perspective. In: principles of gender specific medicine. Lagato MJ (Ed) Elsevier Academic Press. 2004;2:848–59. https://doi.org/10.1016/B978-012440905-7/50349-2.CrossRef

22.

Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J. Women’s. Health (Larchmt). 2005;14(1):19–29. https://doi.org/10.1089/jwh.2005.14.19.CrossRef

23.

Liew CC, Ma J, Tang HC, Zheng R, Dempsey AA. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med. 2006;147:126–32. https://doi.org/10.1016/j.lab.2005.10.005.CrossRefPubMed

24.

Konieczna J, Sanchez J, Van Schothorst EM, et al. Identification of early transcriptome-based biomarkers related to lipid metabolism in peripheral blood mononuclear cells of rats nutritionally programmed for improved metabolic health. Genes Nutr. 2014;9:366. https://doi.org/10.1007/s12263-013-0366-2.CrossRefPubMed

25.

Telle-Hansen VH, Halvorsen B, Dalen KT, Narverud I, Wesseltoft-Rao N, Granlund L, et al. Altered expression of genes involved in lipid metabolism in obese subjects with unfavourable phenotype. Genes Nutr. 2013;8:425–34. https://doi.org/10.1007/s12263-012-0329-z.CrossRefPubMedPubMedCentral

26.

Balasubramanyam M, Premanand C, Mohan V. The lymphocyte as a cellular model to study insights into the pathophysiology of diabetes and its complications. Ann N Y Acad Sci. 2002;958:399–402. https://doi.org/10.1111/j.1749-6632.2002.tb03012.x.CrossRefPubMed

27.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32:S62–7. https://doi.org/10.2337/dc09-S062.CrossRefPubMedCentral

28.

Ghadge AA, Harke SM, Khadke SP, Diwan AG, Pankaj M, Kulkarni OP, et al. Circulatory adipocytokines and lipid profile variations in type-2 diabetic subjects: desirable side-effects of antidiabetic drugs. Diabetes Metab Syndr. 2014;8:230–2. https://doi.org/10.1016/j.dsx.2014.09.010.CrossRefPubMed

29.

Ghadge A, Harke S, Khadke S, Diwan A, Pankaj M, Kulkarni O, et al. Effects of commonly used antidiabetic drugs on antioxidant enzymes and liver function test markers in type 2 diabetes mellitus subjects-pilot study. Exp Clin Endocrinol Diabetes. 2015;123:500–7. https://doi.org/10.1055/s-0035-1554654.CrossRefPubMed

30.

Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–95. https://doi.org/10.2337/diacare.27.6.1487.CrossRefPubMed

31.

Gaines TA, Zhang W, Wang D, Bukun B, Chisholm ST, Shaner DL, et al. Gene amplification confers glyphosate resistance in Amaranthus palmeri. Proc Natl Acad Sci U S A. 2010;107:1029–34. https://doi.org/10.1073/pnas.0906649107.CrossRefPubMed

32.

Ghadge AA, Kuvalekar AA. Controversy of oral hypoglycemic agents in type 2 diabetes mellitus: novel move towards combination therapies. Diabetes Metab Syndr. 2017;11:S5–S13. https://doi.org/10.1016/j.dsx.2016.08.009.CrossRefPubMed

33.

Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona diabetes complications study. Diabetes Care. 2002;25:1135–41. https://doi.org/10.2337/diacare.25.7.1135.CrossRefPubMed

34.

Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:6184–223. https://doi.org/10.3390/ijms15046184.CrossRefPubMedPubMedCentral

35.

Stalder M, Pometta D, Suenram A. Relationship between plasma insulin levels and high density lipoprotein cholesterol levels in healthy men. Diabetologia. 1981;21:544–8. https://doi.org/10.1007/BF00281546.CrossRefPubMed

36.

Pykalisto OJ, Smith PH, Brunzell JD. Determinants of human adipose tissue lipoprotein lipase. Effect of diabetes and obesity on basal- and diet-induced activity. J Clin Investig. 1975;56:1108–17. https://doi.org/10.1172/JCI108185.CrossRefPubMedPubMedCentral

37.

Sadur CN, Yost TJ, Eckel RH. Insulin responsiveness of adipose tissue lipoprotein lipase is delayed but preserved in obesity. J Clin Endocrinol Metab. 1984;59:1176–82. https://doi.org/10.1210/jcem-59-6-1176.CrossRefPubMed

38.

Golay A, Zech L, Shi MZ, et al. High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab. 1987;65:512–8. https://doi.org/10.1210/jcem-65-3-512.CrossRefPubMed

39.

Ahsan S, Ahmed S, Ahmed SD, et al. Status of serum adiponectin related to insulin resistance in prediabetics. J Pak Med Assoc. 2014;64:184–8.PubMed

40.

Ghadge A, Diwan A, Harsulkar A, et al. Gender dependent effects of glycemic status and disease duration on biochemical markers in type 2 diabetes: a pilot study. Diabetes Metab Syndr. 2017;11:S481–9. https://doi.org/10.1016/j.dsx.2017.03.041.CrossRefPubMed

41.

Ghadge AA, Khaire AA, Kuvalekar AA. Adiponectin: a potential therapeutic target for metabolic syndrome. Cytokine Growth Factor Rev. 2018;39:151–8. https://doi.org/10.1016/j.cytogfr.2018.01.004.CrossRefPubMed

42.

Eglit T, Ringmets I, Lember M. Obesity, high-molecular-weight (HMW) adiponectin, and metabolic risk factors: prevalence and gender-specific associations in Estonia. PLoS One. 2013;8:e73273. https://doi.org/10.1371/journal.pone.0073273.CrossRefPubMedPubMedCentral

43.

Lee S, Kwak HB. Role of Adiponectin in metabolic and cardiovascular disease. J Exerc Rehabil. 2014b;10:54–9. https://doi.org/10.12965/jer.140100.CrossRefPubMedPubMedCentral

44.

Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004;279:12152–62. https://doi.org/10.1074/jbc.M311113200.CrossRefPubMed

45.

Sewter C, Berger D, Considine RV, Medina G, Rochford J, Ciaraldi T, et al. Human obesity and type 2 diabetes are associated with alterations in SREBP1 isoform expression that are reproduced ex vivo by tumor necrosis factor-alpha. Diabetes. 2002;51:1035–41. https://doi.org/10.2337/diabetes.51.4.1035.CrossRefPubMed

46.

Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996;37:907–25.CrossRefPubMed

47.

Teran-Garcia M, Adamson AW, Yu G, Rufo C, Suchankova G, Dreesen TD, et al. Polyunsaturated fatty acid suppression of fatty acid synthase (FASN): evidence for dietary modulation of NF-Y binding to the FASN promoter by SREBP-1c. Biochem J. 2007;402:591–600. https://doi.org/10.1042/BJ20061722.CrossRefPubMedPubMedCentral

48.

Ronnebaum SM, Joseph JW, Ilkayeva O, Burgess SC, Lu D, Becker TC, et al. Chronic suppression of acetyl-coa carboxylase 1 in beta-cells impair insulin secretion via inhibition of glucose rather than lipid metabolism. J Biol Chem. 2008;283:14248–56. https://doi.org/10.1074/jbc.M800119200.CrossRefPubMedPubMedCentral

49.

Smith U, Gogg S, Johansson A, Olausson T, Rotter V, Svalstedt B. Thiazolidinediones (PPARgamma agonists) but not PPARalpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB J. 2001;15(1):215–20. https://doi.org/10.1096/fj.00-0020com.CrossRefPubMed

50.

Kadoglou NP, Kapelouzou A, Tsanikidis H, et al. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2011;119(2):63–8. https://doi.org/10.1055/s-0030-1265174.CrossRefPubMed

51.

Koppaka S, Kehlenbrink S, Carey M, Li W, Sanchez E, Lee DE, et al. Reduced adipose tissue macrophage content is associated with improved insulin sensitivity in thiazolidinedione-treated diabetic humans. Diabetes. 2013;62:1843–54. https://doi.org/10.2337/db12-0868.CrossRefPubMedPubMedCentral

52.

Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab. 2016;23:770–84. https://doi.org/10.1016/j.cmet.2016.04.011.CrossRefPubMedPubMedCentral

53.

Giannini C, Santoro N, Caprio S, Kim G, Lartaud D, Shaw M, et al. The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. Diabetes Care. 2011;34:1869–74. https://doi.org/10.2337/dc10-2234.CrossRefPubMedPubMedCentral

54.

Li N, Fu J, Koonen DP, Kuivenhoven JA, Snieder H, Hofker MH. Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance? Atherosclerosis. 2014;233:130–8. https://doi.org/10.1016/j.atherosclerosis.2013.12.013.CrossRefPubMed

55.

Macias-Gonzalez M, Cardona F, Queipo-Ortuno M, et al. PPARgamma mRNA expression is reduced in peripheral blood mononuclear cells after fat overload in patients with metabolic syndrome. J Nutr. 2008;138:903–7. https://doi.org/10.1093/jn/138.5.903.CrossRefPubMed

56.

Phillips CM, Goumidi L, Bertrais S, Field MR, Cupples LA, Ordovas JM, et al. Gene-nutrient interactions with dietary fat modulate the association between genetic variation of the ACSL1 gene and metabolic syndrome. J Lipid Res. 2010;51:1793–800. https://doi.org/10.1194/jlr.M003046.CrossRefPubMedPubMedCentral

57.

Li LO, Mashek DG, An J, Doughman SD, Newgard CB, Coleman RA. Over expression of rat long chain acyl-coa synthetase 1 alters fatty acid metabolism in rat primary hepatocytes. J Biol Chem. 2006;281:37246–55. https://doi.org/10.1074/jbc.M604427200.CrossRefPubMed

58.

Ellis JM, Li LO, Wu PC, Koves TR, Ilkayeva O, Stevens RD, et al. Adipose acyl-coa synthetase-1 directs fatty acids toward beta-oxidation and is required for cold thermogenesis. Cell Metab. 2010;12:53–64. https://doi.org/10.1016/j.cmet.2010.05.012.CrossRefPubMedPubMedCentral

59.

Bunkoczi G, Misquitta S, Wu X, Lee WH, Rojkova A, Kochan G, et al. Structural basis for different specificities of acyltransferases associated with the human cytosolic and mitochondrial fatty acid synthases. Chem Biol. 2009;16:667–75. https://doi.org/10.1016/j.chembiol.2009.04.011.CrossRefPubMedPubMedCentral

60.

Zhang L, Joshi AK, Smith S. Cloning, expression, characterization, and interaction of two components of a human mitochondrial fatty acid synthase. Malonyltransferase and acyl carrier protein. J Biol Chem. 2003;278:40067–74. https://doi.org/10.1074/jbc.M306121200.CrossRefPubMed

61.

Li LO, Ellis JM, Paich HA, Wang S, Gong N, Altshuller G, et al. Liver-specific loss of long chain acyl-coa synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition. J Biol Chem. 2009;284:27816–26. https://doi.org/10.1074/jbc.M109.022467.CrossRefPubMedPubMedCentral

62.

Kanter JE, Kramer F, Barnhart S, Averill MM, Vivekanandan-Giri A, Vickery T, et al. Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-coa synthetase 1. Proc Natl Acad Sci U S A. 2012;109:715–24. https://doi.org/10.1073/pnas.1111600109.CrossRef

63.

Mcardle MA, Finucane OM, Connaughton RM, et al. Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front Endocrinol. 2013;4:52. https://doi.org/10.3389/fendo.2013.00052.CrossRef

64.

Jagannathan-Bogdan M, Mcdonnell ME, Shin H, et al. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J Immunol. 2011;186:1162–72. https://doi.org/10.4049/jimmunol.1002615.CrossRefPubMed

65.

Bruun JM, Pedersen SB, Richelsen B. Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab. 2001;86:1267–73. https://doi.org/10.1210/jcem.86.3.7264.CrossRefPubMed

66.

Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol. 2006;26:611–7. https://doi.org/10.1161/01.ATV.0000201938.78044.75.CrossRefPubMed

67.

Yasser M, Abbas M, Saba H. The effect of metformin on cytokines in Iraqi patients with type 2 diabetes. Innov J Med Sci. 2013;1(3):4–10.

68.

Horvath P, Oliver SR, Zaldivar FP, et al. Effects of intravenous glucose and lipids on innate immune cell activation in healthy, obese, and type 2 diabetic subjects. Phys Rep. 2015;3:2. https://doi.org/10.14814/phy2.12249.CrossRef

69.

Navarro-Gonzalez J, Mora-Fernandez C, Gomez-Chinchon M, et al. Serum and gene expression profile of tumor necrosis factor-alpha and interleukin-6 in hypertensive diabetic patients: effect of amlodipine administration. Int J Immunopathol Pharmacol. 2010;23:51–9. https://doi.org/10.1177/039463201002300105.CrossRefPubMed

70.

Prattichizzo F, Giuliani A, Ceka A, Rippo MR, Bonfigli AR, Testa R, et al. Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes. Clin Epigenetics. 2015;7:56. https://doi.org/10.1186/s13148-015-0090-4.CrossRefPubMedPubMedCentral

71.

Srivastava RAK, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, Newton RS. AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases. J Lipid Res. 2012;53:2490–514. https://doi.org/10.1194/jlr.R025882.CrossRefPubMedPubMedCentral

72.

Huang W, Gou F, Long Y, Li Y, Feng H, Zhang Q, et al. High glucose and lipopolysaccharide activate NOD1- RICK-NF-κB inflammatory signaling in mesangial cells. Exp Clin Endocrinol Diabetes. 2016;124:512–7. https://doi.org/10.1055/s-0042-105641.CrossRefPubMed

Title: Gender dependent differences in lipid metabolism in individuals with type 2 diabetes mellitus
Authors: Abhijit A. Ghadge
Abhay M. Harsulkar
Arundhati G. Diwan
Aniket A. Kuvalekar
Publication date: 01-12-2020
Publisher: Springer International Publishing
Keywords: Insulins
Oral Antidiabetic Drugs
Metformin
Insulins
Type 2 Diabetes
Published in: Journal of Diabetes & Metabolic Disorders / Issue 2/2020
Electronic ISSN: 2251-6581
DOI: https://doi.org/10.1007/s40200-020-00589-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aim

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

Relationship between guanosine triphosphate pathway and tetrahydrobiopterin in gestational diabetes mellitus

Maternal circulating levels of Adipocytokines and insulin resistance as predictors of gestational diabetes mellitus: preliminary findings of a longitudinal descriptive study

Antioxidant activities of Dhanwantaram Kashayam –an Ayurvedic poly herbal formulation alleviates diabetic complications in rats

Assessing impaired fasting blood glucose criteria for high-risk dysglycaemic populations: an experience from a European population state

Vildagliptin ameliorates renal injury in type 2 diabetic rats by suppressing oxidative stress

Predicting type 2 diabetes mellitus among fishermen in Cape Coast: a comparison between the FINDRISC score and the metabolic syndrome

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage